Why MNPR? Monopar Therapeutics Inc. Analysis, Price & AI Insights | Whystock
MNPR
$53.25+1.10 (+2.11%)
Market ClosedLast close May 1
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.